APAC Bioprocessing Facilities 2020

APAC’s Bioprocessing facilities 2020 covers bioprocessing facilities in China, Japan, Korea, Taiwan, SEA, and Australia. The 150 page report covers comprehensive information on parameters of manufacturing capabilities such as facility size, capacity, production technologies, type of biologics manufactured and much more. In addition, the directory features some of the checklists based on DesignFlex30 and highlights examples of companies that have constructed their facilities in a flexible manner catering to the fast-changing needs of the industry. Moreover, in-depth studies on the bioprocessing landscape have supplemented the report with a swot analysis and future forecasts. It provides readers a closer look into the facilities of Chugai, Hanmi, Daiichi Sankyo, Biocon,( India & SEA)  Beigene, Amgen (Singapore), GSK (Singapore), Biocon, AlphaMab, BeiGene, Innovent Biologics, Tot Biopharma.
Report Snapshot
Featured Companies

PURCHASE YOUR REPORT HERE!

For offline payments or inquiries, kindly contact Aisyah Atiqah at

e: aisyah.atiqah@imapac.com

t: +65 3109 0158

Single-User Access

This license grants the right of use of the purchased report to a single recipient only. You may access the material on your computer, as and when required, for your own personal use.

Multi-User Access

Upto 3 users: This license grants the right of use of the purchased report by upto 3 users.

Corporate

Unlimited user access (Within your organization): This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the number of users.

Table Of Contents

Section 1
• Preface
• Report Scope & Data Coverage
• IMAPAC’s Research Methodology

Section 2: Bioprocessing Facilities in Greater China
• Henlius Pharma
• Innovent Biologics
• Pfizer
• Tonhua Dongbao
• AlphaMab
• Akeso Pharmaceuticals
• Hanmi Pharma
• Sinovac
• BeiGene
• Junshi Biosciences
• Tot Biopharma
• Hualan Biological Engineering

Section 3: Bioprocessing Facilities In Korea And Japan
• Samsung Bioepis
• Astellas
• Celltrion
• Chugai
• Hanmi Pharma
• Kyowa Hakko Kirin
• Aprogen Biologiccs
• Daiichi Sankyo

Section 4: Bioprocessing Facilities In India And Australia
• Aurobindo
• CSL Bering
• Serum Institute of India
• CSIRO
• Enzene Biosciences
• Stelis Biopharma

Section 5: Bioprocessing Facilities In South-East-Asia
• Abbvie
• GSK
• AJ Biologics
• Amgen
• Novartis Thailand
• Baxter
• Takeda
• Siam Biosciences

Section 6: Region-Wise Data & Analysis Of Manufacturing Facility {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}
• Products Manufactured: Vaccines| Cell Therapy| Recombinant Proteins & Mabs | Others
• Technologies Housed and Bioprocessing Processes
• Plant Capacity
• Projects In Pipeline
• Biomanufacturing Investment
• Regulatory Approvals
• Facility Size, Design
• Financial Insights
• Pestel Analysis

Section 7: Our Other Reports
• Bibiliography
• Disclaimer
• About Us
• Our Other Reports

Companies Mentioned

• Henlius Pharma
• Innovent Biologics
• Pfizer
• Tonhua Dongbao
• AlphaMab
• Akeso Pharmaceuticals
• Hanmi Pharma
• Sinovac
• BeiGene
• Junshi Biosciences
• Tot Biopharma
• Hualan Biological Engineering
• Samsung Bioepis
• Astellas
• Celltrion
• Chugai
• Hanmi Pharma
• Kyowa Hakko Kirin
• Aprogen Biologiccs
• Daiichi Sankyo
• Aurobindo
• CSL Bering
• Serum Institute of India
• CSIRO
• Enzene Biosciences
• Stelis Biopharma
• Abbvie
• GSK
• AJ Biologics
• Amgen
• Novartis Thailand
• Baxter
• Takeda
• Siam Biosciences

Upcoming Reports

Other Market Research